Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics

Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off‐target effects have limited their use. To...

Full description

Saved in:
Bibliographic Details
Published in:ChemistryOpen (Weinheim) 2015-06, Vol.4 (3), p.335-341
Main Authors: Zong, Hong, Shah, Dhavan, Selwa, Katherine, Tsuchida, Ryan E., Rattan, Rahul, Mohan, Jay, Stein, Adam B., Otis, James B., Goonewardena, Sascha N.
Format: Article
Language:English
Subjects:
Cancer
Conjugates
Dendrimers
Design analysis
Effectiveness
Epigenetics
histone deacetylase (HDAC) inhibitors
Histones
Macrophages
Mathematical models
nanoparticles
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off‐target effects have limited their use. To overcome some of the challenges of traditional HDACi, we sought to use a tumor‐specific dendrimer scaffold to deliver HDACi directly to cancer cells. Here we report the design and evaluation of tumor‐specific dendrimer–HDACi conjugates. The HDACi was conjugated to the dendrimer using an ester linkage through its hydroxamic acid group, inactivating the HDACi until it is released from the dendrimer. Using a cancer cell model, we demonstrate the functionality of the tumor‐specific dendrimer–HDACi conjugates. Furthermore, we demonstrate that unlike traditional HDACi, dendrimer–HDACi conjugates do not affect tumor‐associated macrophages, a recently recognized mechanism through which drug resistance emerges. We anticipate that this new class of cell‐specific epigenetic therapeutics will have tremendous potential in the treatment of cancer. Targeting tumors via epigenetics: Histone deacetylase inhibitors (HDACi) alter the epigenetic state of tumors and are promising therapeutics for cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off‐target effects have limited their use. Here we report the design and evaluation of a tumor‐specific dendrimer–HDACi.
ISSN:2191-1363
2191-1363
DOI:10.1002/open.201402141